The "a, B and C" of Her-2 DNA vaccine development

Cancer Immunology, Immunotherapy

Volumn 57, Issue 11, 2008, Pages 1711-1717

  Wei, Wei Zen ^a   Jacob, Jennifer ^a   Radkevich Brown, Olga ^a   Whittington, Paula ^a   Kong, Yi Chi M ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Autoimmunity; Cancer vaccine; DNA vaccine; ErbB 2; Her 2

Indexed keywords

ADENOVIRUS VECTOR; ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLT3 LIGAND; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE VACCINE; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; TRASTUZUMAB;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE THYROIDITIS; AUTOIMMUNITY; BREAST CARCINOMA; BREAST TUMOR; CANCER IMMUNOTHERAPY; CANCER PATIENT; CONFERENCE PAPER; CROSS REACTION; DERMATITIS; DISEASE PREDISPOSITION; DRUG EFFICACY; ENTEROCOLITIS; GENETIC REGULATION; HEPATITIS; HUMAN; HYPOPHYSITIS; HYPOTHYROIDISM; IMMUNOGENICITY; IMMUNOREACTIVITY; LYMPHOCYTE DEPLETION; MELANOMA; NEOPLASM; NONHUMAN; PLASMID; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RISK; SIDE EFFECT; SUPPRESSOR CELL; THYROTROPIN BLOOD LEVEL; TRANSGENIC MOUSE; TUMOR IMMUNITY; UVEITIS; VIRUS LIKE AGENT;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; RECEPTOR, ERBB-2; T-LYMPHOCYTES, REGULATORY; VACCINES, DNA;

EID: 50649087060     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-008-0464-y     Document Type: Conference Paper

References (53)

1. MC Hung YK Lau 1999 Basic science of HER-2/neu: a review Semin Oncol 26 12 Suppl 4 51 59
2. DJ Slamon W Godolphin LA Jones 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707 712
3. R Ben-Levy HF Paterson CJ Marshall 1994 A single autophosphorylation site confers oncogenicity tothe Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway EMBO J 13 3302 3311
4. T Wada XL Qian MI Greene 1990 Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function Cell 61 1339 1347
5. WZ Wei WP Shi A Galy 1999 Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA Int J Cancer 81 748 754
6. EH Romond EA Perez J Bryant 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684
7. SA Pilon MP Piechocki WZ Wei 2001 Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody J Immunol 167 3201 3206
8. R Kiessling WZ Wei F Herrmann 2002 Cellular immunity to the Her-2/neu protooncogene Adv Cancer Res 85 101 144
9. MP Piechocki SA Pilon WZ Wei 2002 Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA J Immunol Methods 259 33 42
10. SA Pilon C Kelly WZ Wei 2003 Broadening of epitope recognition during immune rejection of ErbB-2-positive tumor prevents growth of ErbB-2-negative tumor J Immunol 170 1202 1208
11. MP Piechocki YS Ho S Pilon 2003 Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines J Immunol 171 5787 5794
12. + T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells Int J Cancer 109 259 264
13. WZ Wei GP Morris YM Kong 2004 Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells Cancer Immunol Immunother 53 73 78
14. F Miller RF Jones J Jacob 2004 From breast cancer immunobiology to her-2 DNA vaccine and autoimmune sequelae Breast Dis 20 43 51
15. + regulatory T cell-depleted mice Cancer Res 65 8471 8478
16. J Jacob O Radkevich G Forni 2006 Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice Cell Immunol 240 96 106
17. MP Piechocki SA Pilon WZ Wei 2001 Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2 J Immunol 167 3367 3374
18. JB Jacob YM Kong C Meroueh 2007 Control of Her-2 tumor immunity and thyroid autoimmunity by MHC and regulatory T cells Cancer Res 67 7020 7027
19. J Ursini-Siegel B Schade RD Cardiff 2007 Insights from transgenic mouse models of ERBB2-induced breast cancer Nat Rev Cancer 7 389 397
20. S Rovero A Amici ED Carlo 2000 DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice J Immunol 165 5133 5142
21. MP Piechocki GH Yoo SK Dibbley 2007 Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu Cancer Res 67 6825 6843
22. + T cells: a common basis between tumor immunity and autoimmunity J Immunol 163 5211 5218
23. RT Reilly MB Gottlieb AM Ercolini 2000 HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice Cancer Res 60 3569 3576
24. R Singh Y Paterson 2007 In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines Cancer Immunol Immunother 56 927 938
25. + T-cell repertoire Cancer Res 65 6443 6449
26. P Gallo S Dharmapuri M Nuzzo 2005 Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector Int J Cancer 113 67 77
27. SM Pupa M Iezzi CE Di 2005 Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination Cancer Res 65 1071 1078
28. K Tegerstedt JA Lindencrona C Curcio 2005 A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors Cancer Res 65 5953 5957
29. W Huang GD Kukes 1999 Hashimoto's thyroiditis: an organ-specific autoimmune disease-pathogenesis and recent developments Lab Invest 79 1175 1180
30. GW Canonica ME Cosulich R Croci 1984 Thyroglobulin-induced T-cell in vitro proliferation in Hashimoto's thyroiditis: identification of the responsive subset and effect of monoclonal antibodies directed to Ia antigens Clin Immunol Immunopathol 32 132 141
31. B Vaidya P Kendall-Taylor SHS Pearce 2002 Genetics of endocrine disease: the genetics of autoimmune thyroid disease J Clin Endocrinol Metab 87 5385 5397
32. YM Kong LC Lomo RW Motte 1996 HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA-DRB1*0301 (DR3) gene J Exp Med 184 1167 1172
33. YM Kong CS David LC Lomo 1997 Role of mouse and human class II transgenes in susceptibility to and protection against mouse autoimmune thyroiditis Immunogenetics 46 312 317
34. AO Vladutiu NR Rose 1971 Autoimmune murine thyroiditis: relation to histocompatibility (H-2) type Science 174 1137 1139
35. CE Larsen CA Alper 2004 The genetics of HLA-associated disease Curr Opin Immunol 16 660 667
36. L Levin Y Ban E Concepcion 2004 Analysis of HLA genes in families with autoimmune diabetes and thyroiditis Hum Immunol 65 640 647
37. PS Esquivel NR Rose YM Kong 1977 Induction of autoimmunity in good and poor responder mice with mouse thyroglobulin and lipopolysaccharide J Exp Med 145 1250 1263
38. M Elrehewy YM Kong AA Giraldo 1981 Syngeneic thyroglobulin is immunogenic in good responder mice Eur J Immunol 11 146 151
39. DG McNeel KL Knutson K Schiffman 2003 Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant J Clin Immunol 23 62 72
40. ML Disis K Rinn KL Knutson 2002 Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers Blood 99 2845 2850
41. EM Shevach 2000 Regulatory T cells in autoimmmunity Annu Rev Immunol 18 423 449
42. + cells as mediators of boththyroglobulin-activated and TSH-induced suppression Clin Immunol Immunopathol 51 38 54
43. S Sakaguchi N Sakaguchi M Asano 1995 Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases J Immunol 155 1151 1164
44. + regulatory T cells in induced tolerance to experimental autoimmune thyroiditis Cell Immunol 226 20 29
45. + regulatory T cells: a potential role in reciprocal inhibition by class II genes in autoimmune thyroiditis J Immunol 174 3111 3116
46. GP Morris YM Kong 2006 Interference with CD4(+)CD25(+) T-cell-mediated tolerance to experimental autoimmune thyroiditis by glucocorticoid-induced tumor necrosis factor receptor monoclonal antibody J Autoimmun 26 24 31
47. AV Maker P Attia SA Rosenberg 2005 Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade J Immunol 175 7746 7754
48. JA Blansfield KE Beck K Tran 2005 Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer J Immunother 28 593 598
49. P Attia GQ Phan AV Maker 2005 Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 J Clin Oncol 23 6043 6053
50. AV Maker GQ Phan P Attia 2005 Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study Ann Surg Oncol 12 1005 1016
51. MR Robinson CC Chan JC Yang 2004 Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis J Immunother 27 478 789
52. GQ Phan JC Yang RM Sherry 2003 Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma Proc Natl Acad Sci USA 100 8372 8377
53. Rose NR, Bacon LD, Sundick RS et al (1977) Genetic regulation in autoimmune thyroiditis. In: Talal N (ed) Autoimmunity: genetics, immunologic, virologic, and clinical aspects. Academic Press, New York, pp 63-87